From: Blinded by numbers, first published in August 2007.
Insurers and governments don’t want to pay for drugs that don’t work but only 40% of patients respond to prescription medicines in the CNS area. There are also a lot of drugs that don’t make it through clinical trials because the results are not good enough. Yet many of these drugs would work on particular subgroups. Homomatrix can select the patients most likely to respond to a particular drug in clinical trials thereby reducing the risk and cost of developing new treatments. It can cost up to $1.2bn (£600m) to get one drug onto the market. Homomatrix can also stop existing drugs being prescribed to people who will not respond to them. Read more 'Curidium Medica'